

Table S5. Post-vaccination immunogenicity for participants receiving 1 dose of IIV4

Measure	Strain	Half dose of IIV4		Full dose of IIV4		Comparison (95% CI)
		N	Value (95% CI)	N	Value (95% CI)	
HAI GMT	A(H1N1)	250	315 (264–377)	267	387 (326–459)	1.23 (0.959–1.57) ^a
	A(H3N2)	252	235 (189–290)	268	343 (279–422)	1.46 (1.09–1.97) ^a
	B/Victoria	250	389 (326–464)	267	523 (445–616)	1.35 (1.06–1.71) ^a
	B/Yamagata	251	360 (305–425)	269	513 (435–606)	1.42 (1.13–1.80) ^a
Seroconversion rate (%)	A(H1N1)	228	81.1 (75.4–86.0)	245	82.0 (76.7–86.6)	0.9 (–6.07–7.94) ^b
	A(H3N2)	230	78.7 (72.8–83.8)	246	80.1 (74.5–84.9)	1.4 (–5.87–8.69) ^b
	B/Victoria	228	89.5 (84.7–93.1)	245	92.7 (88.6–95.6)	3.2 (–2.01–8.54) ^b
	B/Yamagata	229	91.7 (87.3–94.9)	247	93.9 (90.2–96.6)	2.2 (–2.49–7.13) ^b
Post- to pre- vaccination GMT ratio	A(H1N1)	228	10.1 (8.62–11.9)	245	12.4 (10.4–14.7)	-
	A(H3N2)	230	11.3 (9.37–13.7)	246	12.8 (10.5–15.5)	-

Measure	Strain	Half dose of IIV4		Full dose of IIV4		Comparison (95% CI)
		N	Value (95% CI)	N	Value (95% CI)	
	B/Victoria	228	11.8 (10.2–13.6)	245	17.4 (15.1–20.1)	-
	B/Yamagata	229	13.2 (11.5–15.1)	247	19.4 (16.9–22.2)	-

Immunogenicity was assessed according to the vaccine received in all participants in the immunogenicity subset who received at least one dose of the study vaccine, had a valid post-vaccination serology result for at least one strain, and completed the study according to protocol. Abbreviations: CI, confidence interval; GMT, geometric mean titer; HAI, hemagglutination inhibition; IIV4, quadrivalent split-virion inactivated influenza vaccine; -, not calculated/determined.

^a Ratio of HAI GMTs (full dose/half dose).

^b Difference in seroconversion rate: seroconversion rate for the full dose of IIV4 minus the seroconversion rate for the half dose of IIV4.